Spotlight · Life Sciences
Jean Bennett Honored with 2026 Breakthrough Prize for Pioneering Retinal Gene Therapy
Published November 07, 2026
Recognition for transforming treatment of inherited blindness through gene replacement therapy
The 2026 Breakthrough Prize in Life Sciences was awarded to Jean Bennett, Katherine A. High, and Albert Maguire for their pioneering work in gene therapy that has transformed the treatment of inherited blindness.
A Landmark Gene Therapy
The trio developed the first FDA-approved gene replacement therapy for Leber congenital amaurosis, a rare genetic disorder causing early-onset blindness. Their therapy replaces the malfunctioning RPE65 gene, critical for the retina's response to light, restoring vision in affected patients.
From Concept to Clinical Success
Bennett and Maguire initially demonstrated the therapy's effectiveness in animal models, including restoring sight in dogs. High's expertise was crucial in advancing the therapy through clinical trials and regulatory approval, ensuring high-quality viral vector production and validating novel clinical endpoints.
Impact and Legacy
Nearly all eligible patients in the U.S. have received the treatment, with durable vision improvements lasting over a decade. Beyond its immediate benefits, this breakthrough established pathways that have enabled over 100 retinal gene therapy trials worldwide, opening new horizons for treating genetic diseases.
Sources
- Breakthrough Prize Announces 2026 Laureates | Breakthrough Prize
- Jean Bennett ’72 DPH Awarded ‘Oscar of Science’ for Work in Gene Therapy and Blindness
- Jean Bennett | Faculty | About Us | Perelman School of Medicine | Perelman School of Medicine at the University of Pennsylvania
This is an independent IQMIA editorial feature, not an endorsement or statement by the people mentioned.